Medication for borderline personality disorder: A survey at a secure hospital

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 4, 2011, Pages 270-274

  Haw, Camilla ^a   Stubbs, Jean ^a  

^a ST ANDREW S HOSPITAL   (United Kingdom)

Author keywords

Borderline personality disorder; Clozapine; Forensic psychiatry; Psychotropic medication

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DIAZEPAM; LAMOTRIGINE; LORAZEPAM; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; PREGABALIN; PROMETHAZINE; PROPRANOLOL; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ADULT; AGGRESSION; AGITATION; ANXIETY; AROUSAL; BORDERLINE STATE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISSOCIATION; DRUG DOSE COMPARISON; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH SURVEY; HUMAN; HYPERSALIVATION; IMPULSIVENESS; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MENTAL INSTABILITY; OFF LABEL DRUG USE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 80054007173     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.590211     Document Type: Review

References (24)

1. Stern A. Psychoanalytic investigation of and therapy in the borderline group of neuroses. Psychoanal Q 1938;7:467-89.
2. Coid J, Yang M, Bebbington P, Moran P, Brugha T, Jenkins R, et al. Borderline personality disorder: Health service use and social functioning among a national household population. Psychol Med 2009;39:1721-31.
3. Winston AP. Recent developments in borderline personality disorder. Adv Psychiatr Treat 2000;6:211-17.
4. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HI, et al. Two-year randomized controlled trial and follow-up of dialectical behaviour therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006;63:757-66.
5. Zanarini MC, Frankenburg FR, Dobo ED, Sickel AE, Trikha A, Levin A, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998;155:1733-9. (Pubitemid 28547499)
6. Lart R, Payne S, Beaumont B, MacDonald G, Mistry T. Women and secure psychiatric services: A literature review. York: NHS Centre for Reviews and Dissemination, University of York; 1999.
7. National Institute for Health and Clinical Excellence. Borderline personality disorder: Treatment and management [updated 22 March 2011; cited 26 March 2011] (Available from: http://www.nice.org.uk/CG78).
8. Lieb K, Völ lm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010; 196:4-12.
9. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. Comp Psychiatry 2001;42:144-50. (Pubitemid 32207250)
10. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004;65:28-36.
11. Mental Health Act 2007 [cited 26 March 2011] (Available at: www.legislation.gov.uk/ukpa/2007/12/contents).
12. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary No. 60. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
14. SPSS Inc. SPSS for Windows release 14.0.2. Chicago, IL: SPSS Inc; 2006.
15. Ventura MA, Green MF, Shaner A, Liberman RP. Training and quality assurance with the brief psychiatric rating scale: " The drift buster " . Int J Methods Psychiatr Res 1993;3:221-44.
16. Baker-Glenn E, Steels M, Evans C. Use of psychotropic medication among psychiatric out-patients with personality disorder. Psychiatrist 2010;34:83-6.
17. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59:103-7. (Pubitemid 28150854)
18. Chegappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999;60:477-84. (Pubitemid 29369804)
19. Swinton M. Clozapine in severe borderline personality disorder. J Forensic Psychiatry 2001;12:580-91. (Pubitemid 34071234)
20. Taylor D, Paton C, Kapur S. Maudsley prescribing guidelines. London: Informa Healthcare; 2009.
21. Royal College of Psychiatrists. Use of licensed medicines for unlicensed applications in psychiatric practice (College Report CR142). London: Royal College of Psychiatrists; 2007.
22. Zimmerman M, McGlinchey JB, Chelminski I, Young D. Diagnostic co-morbidity in 2300 psychiatric out-patients presenting for treatment evaluated with a semi-structured diagnostic interview. Psychol Med 2008;38:199-210. (Pubitemid 351156594)
23. Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry 1999;40: 245-52. (Pubitemid 29319237)
24. Zanarini MC, Frankenburg FR, Dubo ED, Sickel AE, Trikha A, Levin A, et al. Axis II comrbidity of borderline personality disorder. Compr Psychiatry 1998;39:296-302. (Pubitemid 28425920)